Questions/answers on Circulating calprotectin as an important tool in autoinflammatory disorders
Circulating calprotectin can replace faecal calprotectin measurement either due to patient compliance or logistical requirements. Additionally there are recent evidences showing plasma calprotectin as marker of disease activity in ulcerative Colitis. (Malham M, et al. Scand J Gastroenterol. 2019 Oct;54(10):1214-1219. )
The high value is both for diagnostic and prognostic applications. Given the limited value of conventional acute phase reactants in some RA patients the identification of further biomarkers could provide advantages in the identification of new patients and in the management of the disease. Calprotectin is more accurate than ESR and CRP in detecting power doppler ultrasound synovitis in RA and PsA patients in the very early phase of diseases. Serum calprotectin levels are a strong predictor of response to biological treatments in patients with RA. This is very important for its potential for personalizing biological treatment and prediction of response in RA patients using calprotectin levels + clinical predictors (precision medicine).
In COVID-19 patients calprotectin levels were reported to be associated with poor clinical outcomes. It is also able to identify patients with severe pulmonary disease. (Aceti A, et al. Sci Rep 2020, 10(1):18665; Shi H, et al. medRxiv 2020.)
Calprotectin may replace or support the traditional markers of inflammation. Moreover they should be included in the classification criteria for RA.
Calprotectin levels decrease rapidly during treatment with TNF-a-inhibitors in both axial and peripheral SpA. Baseline calprotectin levels were found to be an independent predictor of radiographic spinal progression in axial SpA. Calprotectin concentration >0.5 mg/mL was associated with worsening of the modified Stoke Ankylosing Spondylitis Spine Score and the development or progression of syndesmophytes at the two year follow-up.(Turina MC,et al.Ann Rheum Dis 2014;73:1746–8)